Lung function in a group of Czech infants with cystic fibrosis
Authors:
V. Koucky; V. Skalická; J. Bartošová; T. Doušová; V. Vávrová; P. Pohunek
Authors place of work:
Pediatrická klinika 2. LF UK a FN Motol, Praha
Published in the journal:
Čes-slov Pediat 2019; 74 (7): 392-400.
Category:
Summary
Objective: To assess lung function in a group of Czech infants with cystic fibrosis (CF) and to evaluate safety of the infant pulmonary function testing (iPFT) in these patients.
Methods: Fifty-five infants (age range 5–118 weeks) with classic form of CF clinically indicated for iPFT in our lab were sedated with chloralhydrate and underwent multiple breath inert gas washout test, bodypletysmography, tidal breath analysis, single occlusion compliance-resistance measurement and tidal volume rapid thoracoabdominal compression. During iPFT and until full recovery from sedation, haemoglobin saturation, pulse rate, minute ventilation and clinical correlates of lung aspiration were monitored. Lung function was compared to the available international normative values and between clinically defined subgroups (based on patient’s age, microbial colonisation, occurrence of severe pulmonary exacerbations (PEx), history of meconium ileus and exocrine pancreatic function).
Results: Lung function impairment was detected in 63.9% of infants with the most frequent impairment being ventilation inhomogeneity (51.2% of all), followed by hyperinflation (48.6% of all) and peripheral airway obstruction (50.0% of all). Lung function was significantly diminished in older patients (mean age 16.6 vs 2.0 months), patients with at least one PEx, intermittent Pseudomonas aeruginosa and chronic Staphylococcus aureus colonization. Only 1 adverse event occurred – brief desaturation down to 85%.
Conclusion: Lung function impairment may be detected by iPFT as early as in 2 months-aged CF infants, its frequency increases with age. Lung function differs between clinically defined subgroups of patients. iPFT is safe.
Keywords:
Cystic fibrosis – Infants – toddler – multiple breath inert gas washout test – bodypletysmography – tidal breath analysis – single occlusion compliance-resistance measurement – tidal volume rapid thoracoabdominal compression – Safety
Zdroje
1. Hoo AF, Thia LP, Nguyen TT, et al.; London Cystic Fibrosis Collaboration. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012; 67: 874–881.
2. Sly PD, Brennan S, Gangell C, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180 (2): 146–152.
3. Mott LS, Park J, Murray CP, et al.; AREST CF. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67 (6): 509–516.
4. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018; 17 (2): 153–178.
5. Hulskamp G, Pillow JJ, Dinger J, et al. Lung function tests in neonates and infants with chronic lung disease of infancy: functional residual capacity. Pediatr Pulmonol 2006; 41: 1–22.
6. Gappa M, Colin AA, Goetz I, et al. Passive respiratory mechanics: the occlusion techniques. Eur Respir J 2001; 17: 141–148.
7. Gappa M, Pillow JJ, Allen J, et al. Lung function tests in neonates and infants with chronic lung disease: lung and chest-wall mechanics. Pediatr Pulmonol 2006; 41 (4): 291–317.
8. Bates JH, Schmalisch G, Filbrun D, et al. Tidal breath analysis for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/American Thoracic Society. Eur Respir J 2000; 16 (6): 1180–1192.
9. Lum S, Hülskamp G, Merkus P, et al. Lung function tests in neonates and infants with chronic lung disease: forced expiratory maneuvers. Pediatr Pulmonol 2006; 41 (3): 199–214.
10. Sly PD, Tepper R, Henschen M, et al. Tidal forced expirations. ERS//ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/American Thoracic Society. Eur Respir J 2000; 16 (4): 741–748.
11. Robinson PD, Latzin P, Verbanck S, et al. Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J 2013; 41 (3): 507–522.
12. Nguyen TT, Hoo AF, Lum S, et al. New reference equations to improve interpretation of infant lung function. Pediatr Pulmonol 2013; 48 (4): 370–380.
13. Jones M, Castile R, Davis S, et al. Forced expiratory flows and volumes in infants. Normative data and lung growth. Am J Respir Crit Care Med 2000; 161: 353–359.
14. Ranganathan SC, Goetz I, Hoo AF, et al.; London Collaborative Cystic Fibrosis Group. Assessment of tidal breathing parameters in infants with cystic fibrosis. Eur Respir J 2003; 22 (5): 761–766.
15. Lum S, Stocks J, Stanojevic S, et al. Age and height dependence of lung clearance index and functional residual capacity. Eur Respir J 2013; 41 (6): 1371–1377.
16. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med 2016; 4 (8): 662–674.
17. Kieninger E, Yammine S, Korten I, et al.; SCILD Study Group; BILD Study Group. Elevated lung clearance index in infants with cystic fibrosis shortly after birth. Eur Respir J 2017; 50 (5). Pii: 1700580.
18. Lum S, Gustafsson P, Ljungberg H, et al.; London Cystic Fibrosis Collaboration. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007; 62 (4): 341–347.
19. Davies G, Aurora P. The use of multiple breath washout for assessing cystic fibrosis in infants. Expert Rev Respir Med 2017; 11 (1): 21–28.
20. Koucký V, Skalická V, Pohunek P. Nitrogen multiple breath washout test for infants with cystic fibrosis. Eur Respir J 2018; 52 (2). Pii: 1800015.
21. Nguyen TT, Thia LP, Hoo AF, et al.; London Cystic Fibrosis Collaboration (LCFC). Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants. Thorax 2014; 69 (10): 910–917.
22. Davies G, Stocks J, Thia LP, et al.; London Cystic Fibrosis Collaboration (LCFC). Pulmonary function deficits in newborn screened infants with cystic fibrosis managed with standard UK care are mild and transient. Eur Respir J 2017; 50 (5). Pii:1800015.
23. Pillarisetti N, Williamson E, Linnane B, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184 (1): 75–81.
24. Zatím nepublikovaná data z osobní komunikace Gustafsson P, Lindblad A.
25. Sullivan L, Forno E, Pedersen K, et al. Nitrogen back-diffusion during multiple-breath washout with 100% oxygen. Eur Respir J 2017; 50 (3). Pii: 1700679.
26. Gustafsson PM, Bengtsson L, Lindblad A, et al. The effect of inert gas choice on multiple breath washout in healthy infants: differences in lung function outcomes and breathing pattern. J Appl Physiol (1985) 2017; 123: 1545–1554.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2019 Číslo 7
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Cystic fibrosis newborn screening and CFSPID diagnostics
- Viscoelastic method rotational thromboelastometry (ROTEM)
- Historie cystické fibrózy u nás – editorial
- Ten years of neonatal screening of cystic fibrosis in Slovakia